LTA4H rs2660845 association with montelukast response in early and late-onset asthma

Authors:

Abstract
Leukotrienes play a central pathophysiological role in both paediatric and adult asthma. However, 35% to 78% of asthmatics do not respond to leukotriene inhibitors. In this study we tested the role of theLTA4Hregulatory variant rs2660845 and age of asthma onset in response to montelukast in ethnically diverse populations. We identified and genotyped 3,594 asthma patients treated with montelukast (2,514 late-onset and 1,080 early-onset) from seven cohorts (UKBiobank, GoSHARE, BREATHE, Tayside RCT, PAGES, GALA II and SAGE). Individuals under montelukast treatment experiencing at least one exacerbation in a 12-month period were compared against individuals with no exacerbation, using logistic regression for each cohort and meta-analysis. While no significant association was found with European late-onset subjects, a meta-analysis of 523 early-onset individuals from European ancestry demonstrated the odds of experiencing asthma exacerbations by carriers of at least one G allele, despite montelukast treatment, were increased (odds-ratio = 2.92, 95%confidence interval (CI): 1.04–8.18, I2 = 62%, p = 0.0412) compared to those in the AA group. When meta-analysing with other ethnic groups, no significant increased risk of asthma exacerbations was found (OR = 1.60, 95% CI: 0.61–4.19, I2 = 85%, p = 0.342). Our study demonstrates that genetic variation inLTA4H, together with timing of asthma onset, may contribute to variability in montelukast response. European individuals with early-onset (≤18y) carrying at least one copy of rs2660845 have increased odd of exacerbation under montelukast treatment, presumably due to the up-regulation ofLTA4Hactivity. These findings support a precision medicine approach for the treatment of asthma with montelukast.
All Related Versions
Funding Information
  • Scottish Enterprise Tayside
  • Gannochy Trust
  • Perth and Kinross City Council
  • Brighton and Sussex Medical School
  • Merck, Sharpe & Dohme, United Kingdom
  • Chief Scientist Officer for Scotland
  • Biomedical Resource (099177/Z/12/Z)
  • Wellcome Trust (Award 072960 and 084726)
  • UK Medical Research Council (G0601261)
  • Instituto de Salud Carlos III (AC15/00015)
  • ZonMw (9003035001)
  • Ministry of Education, Science and Sport of the Republic of Slovenia (C330-16-500106)
  • German Ministry of Education and Research (BMBF (FKZ 031L0088)
  • Instituto de Salud Carlos III (AC15/00058)
  • European Regional Development Fund (PT17/0019, of the PE I+D+i 2013-2016)
  • National Heart, Lung, and Blood Institute (R01HL117004)
  • National Institutes of Health (X01HL134589)
  • Sandler Family Foundation
  • American Asthma Foundation
  • Robert Wood Johnson Foundation
  • Harry Wm. and Diana V. Hind Distinguished Professorship in Pharmaceutical Sciences II
  • National Institute of Environmental Health Sciences (R01ES015794)
  • National Heart, Lung, and Blood Institute (R01HL128439, R01HL135156, R01HL141992, and R01HL141845)
  • National Institute of Environmental Health Sciences (R21ES24844)
  • National Institute on Minority Healthand Health Disparities (P60MD006902, R01MD010443, and R56MD013312)
  • National Institute of General Medical Sciences (RL5GM118984)
  • Tobacco-Related Disease Research Program (24RT-0025 and 27IR-0030)
  • National Human Genome Research Institute (U01HG009080)
  • AstraZeneca Schweiz
  • Spanish Ministry of Science, Innovation and Universities (PRE2018-083837)
  • Ramón y Cajal Program by the Spanish Ministry of Economy, Industry and Competitiveness (RYC-2015-17205)
  • European Social Funds from the European Union (FI16/00136)

This publication has 49 references indexed in Scilit: